ArticleJournal of pharmacy & bioallied sciences2024
The Study to Assess the Effectiveness of Cissus Quadrangularis among Postmenopausal Women with Osteopenia.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Role ofOrthopedic research and reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteopenia refers to bone density that is not only normal but also not as low as that noted in osteoporosis. Osteopenia leads to osteoporosis and increases the risk of fractures. Current research is focused on agents that will prevent or slow the progression of bone loss. The Objectives of the Study: To assess the pretest and posttest levels of osteopenia among postmenopausal women, and to assess the effectiveness of Cissus quadrangularis (CQ) on postmenopausal women with osteopenia. Methodology: A true experimental study design using targeted sampling techniques was used to conduct 60 patients with osteopenia. The data were collected with the help of structured questionnaires. Confidentiality was maintained throughout the process. The data collected were analyzed using descriptive and inference statistics. Result: A total of 60 participants completed this study. The percent BMD changes in the CQ-treated groups did not differ at any site after 24 weeks compared to the placebo. Reduced bone remodeling activity was detected in both CQ-treated groups. These results correlated with the within-group comparison, which showed a continuously significant increase in both BTMs in the placebo group. Conclusion: This is the first clinical report that showed a promising effect on delaying bone loss of oral administration of CQ for 24 weeks, as indicated by a slower bone remodeling process via a reduction in BTMs. However, no change in BMD was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.